Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Apr. 19, 2022
Jun. 30, 2021
Cover [Abstract]      
Entity Registrant Name Zivo Bioscience, Inc.    
Entity Central Index Key 0001101026    
Document Type 10-K/A    
Amendment Flag true    
Entity Voluntary Filers No    
Current Fiscal Year End Date --12-31    
Entity Well Known Seasoned Issuer No    
Entity Small Business true    
Entity Shell Company false    
Entity Emerging Growth Company false    
Entity Current Reporting Status Yes    
Document Period End Date Dec. 31, 2021    
Entity Filer Category Non-accelerated Filer    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Entity Common Stock Shares Outstanding   9,419,660  
Entity Public Float     $ 29.2
Auditor Name BDO USA, LLP    
Auditor Location Troy, Michigan    
Auditor Firm Id 243    
Document Annual Report true    
Entity File Number 001-40449    
Entity Incorporation State Country Code NV    
Entity Tax Identification Number 87-0699977    
Entity Interactive Data Current Yes    
Icfr Auditor Attestation Flag false    
Entity Address Address Line 1 21 East Long Lake Road    
Entity Address Address Line 2 Suite 100    
Entity Address City Or Town Bloomfield Hills    
Entity Address State Or Province MI    
Entity Address Postal Zip Code 48304    
City Area Code 248    
Local Phone Number 452 9866    
Security 12b Title Common Stock, $0.001 par value per share    
Trading Symbol ZIVO    
Security Exchange Name NASDAQ    
Document Transition Report false    
Amendment Description Zivo Bioscience, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the year ended December 31, 2021, as filed on April 22, 2022 (the “Original Form 10-K”) with the Securities and Exchange Commission (the “SEC”), solely to provide the Part III information of Form 10-K that was to be incorporated by reference from the Company’s definitive proxy statement for its 2022 Annual Meeting of Stockholders (the “Proxy Statement”) because the Proxy Statement will not be filed with the SEC within 120 days after the end of the Company’s fiscal year ended December 31, 2021. This Form 10-K/A hereby amends and restates in their entirety Items 10 through 14 of Part III of the Original Form 10-K. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as Exhibits 31.1 and 31.2 to this Amendment under Item 15 of Part IV hereof. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Except as described above, no other changes have been made to the Original Form 10-K, and this Amendment does not amend, update or change any other items or disclosures in the Original Form 10-K. The Original Form 10-K continues to speak as of its original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form 10-K or modify or update in any way disclosures in the Original Form 10-K.